Fibromyalgia patients report pain, fatigue and multiple therapies at FDA hearing
Chronic pain, fatigue, difficulty concentrating and sleep problems were the top symptoms discussed by patients with fibromyalgia during today’s FDA public meeting on patient-focused drug development. The patients reported multimodal treatments that included FDA-approved and over-the-counter drugs, herbal remedies and exercise. Adverse events and high costs of treatments were concerns brought up by many in attendance.
The meeting was moderated by Sara Eggers, PhD, Office of Strategic Programs, Center for Drug Evaluation and Research (CDER), FDA.